Physician profile
Eric D Delgado
NPI 1417034018
$4,252.20
in general payments reported to CMS, 2019-2025
12 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $334 · 2021: $126 · 2022: $111 · 2023: $1,035 · 2024: $811 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,146.83 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $834.61 | 2022-2025 | Infuse, Biotrue, Biotrue One Day |
| Alcon Vision LLC | $797.95 | 2020-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $336.19 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $266.50 | 2019-2020 | |
| Glaukos Corporation | $239.37 | 2025 | Idosetr |
| Lkc Technologies, INC. | $179.20 | 2025 | |
| Sight Sciences, INC. | $139.91 | 2019 | |
| Biotissue Holdings INC. | $136.89 | 2025 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2020 | |
| Dompe US, INC. | $27.64 | 2024 | Oxervate |
| Gilead Sciences, INC. | $22.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.